The analyst rating from BofA Securities for WUXI BIO is reiterated as Neutral due to the company's positive profit alert, which estimates a 16.7% year-over-year revenue growth to RMB21.8 billion for 2025. This performance aligns with the broker's expectations and is driven by a record number of new projects and expanded service offerings, particularly in the BsAb and ADC platforms. Additionally, the target price has been raised from HKD41.8 to HKD47, reflecting a positive outlook while maintaining a Neutral stance.
